IMDX · Insight Molecular Diagnostics Inc.
$4.13
+0.01 (+0.24%)
At close · Sep 4
Going-concern doubt
— cleared Aug 10, 2026
The latest filing states the doubt was alleviated.
“Our expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that the consolidated financial statements are issued. ... Management has concluded that it is probable that our plans will be effectively implemented and that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about our ability to continue as a going concern within one year after the date of issuance of these consolidated financial statements. ... Accordingly, management has concluded that substantial doubt does not exist about the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.”View the 10-Q filed Aug 10, 2026
Market Cap
$135.15M
Shares
32.72M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$4.06M
+115.6%
FY2025
Net Income
-$50.22M
+17.2%
FY2025
Gross Margin
56.67%
+17.3pp
FY2025
Operating Margin
-1260.76%
+1984.4pp
FY2025
Diluted EPS
-$1.65
+64.6%
FY2025
Operating Cash Flow
-$22.18M
-7.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.67M | $4.06M | $1.88M | $1.5M | $958K | $2.2M | $1.22M | — | — | — | — | $0 | — | |
| -$98K | -$109K | -$84K | -$52K | -$83K | -$209K | -$252K | $299K | -$216K | -$217K | -$28K | -$19K | -$2000 | |
| $856K | $1.75M | $1.05M | $1M | $880K | $697K | $1.86M | — | — | — | — | — | — | |
| $807K | $2.3M | $740K | $413K | -$18K | $1.42M | -$639K | — | — | — | — | — | — | |
| — | 56.67% | 39.34% | 27.48% | -1.88% | 64.6% | -52.55% | — | — | — | — | — | — | |
| $19.15M | $15.9M | $9.84M | $9.29M | $7.3M | $5.04M | $9.8M | $6.79M | $6.51M | $7.17M | $5.68M | $4.53M | $3.96M | |
| $8M | $6.34M | $3.94M | $2.8M | $1.13M | $552K | $6.49M | $2.16M | $1.68M | $2.44M | $1.2M | $324K | — | |
| $10.74M | $10.63M | $10.2M | $11.18M | $21.88M | $22.29M | $16.79M | $13.28M | $7.01M | $9.23M | $4.27M | $3.87M | $1.01M | |
| $0 | $7000 | $88K | $88K | $3.69M | $3.36M | $81K | — | $121K | $242K | $242K | $242K | $242K | |
| $2.44M | $2.2M | $1.56M | $1.68M | $1.53M | $800K | $313K | — | — | — | — | — | — | |
| $51.11M | $53.42M | $61.78M | $25.55M | $17.98M | $55.15M | $29.07M | $22.24M | $15.2M | $18.85M | $11.14M | $8.72M | $4.97M | |
| -$50.3M | -$51.12M | -$61.04M | -$25.14M | -$18M | -$53.73M | -$29.71M | -$22.24M | -$15.2M | -$18.85M | -$11.14M | -$8.72M | -$4.97M | |
| — | -1260.76% | -3245.14% | -1672.39% | -1878.6% | -2444.27% | -2443.34% | — | — | — | — | — | — | |
| -$47.86M | -$48.93M | -$59.48M | -$23.46M | -$16.47M | -$52.93M | -$29.4M | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | $0 | $18K | $0 | |
| $939K | $902K | $378K | $281K | -$615K | $854K | -$1.48M | -$187K | -$552K | -$526K | -$28K | -$17K | -$13K | |
| — | — | — | — | — | -$270K | -$1.55M | -$281K | — | — | — | — | — | |
| — | — | -$60.66M | -$24.86M | -$18.61M | -$52.87M | -$31.19M | -$22.43M | — | — | — | — | — | |
| $0 | $0 | $0 | $0 | — | -$9.26M | -$1.25M | — | — | — | — | — | — | |
| -$49.36M | -$50.22M | -$60.66M | -$27.78M | -$72.9M | -$64.1M | -$29.93M | -$22.43M | -$15.75M | -$19.38M | -$11.17M | -$8.74M | -$4.99M | |
| — | -1238.52% | -3225.04% | -1848.37% | -7609.81% | -2916.15% | -2461.51% | — | — | — | — | — | — | |
| — | -$50.22M | -$60.93M | -$28.72M | -$73.42M | -$64.1M | — | — | — | — | — | — | — | |
| -$49.38M | -$50.16M | -$60.69M | -$27.77M | -$72.9M | -$64.06M | -$29.93M | -$22.43M | -$15.75M | -$19.61M | -$11.47M | -$8.26M | -$4.44M | |
| USD/shares | -$1.52 | -$1.65 | -$4.66 | -$3.75 | -$13.25 | -$14.40 | — | — | — | — | — | — | — |
| USD/shares | -$1.52 | -$1.65 | -$4.66 | -$3.75 | -$13.25 | — | — | — | — | — | — | — | — |
| shares | — | 30.48M | 13.07M | 7.65M | 5.54M | 4446 | 3273.9 | 2.56M | 1.89M | 1.51M | 1.33M | 1.05M | 910K |
| shares | — | 30.48M | 13.07M | 7.65M | 5.54M | 4446 | 3273.9 | 2.56M | 1.89M | 1.51M | 1.33M | 1.05M | 910K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.10×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 12 similar-size Diagnostics & Research companies (of 48 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| United States | $4,031,000 | $1,673,000 | $923,000 |
| Europe | $24,000 | $18,000 | — |
| United Kingdom | $0 | $45,000 | $409,000 |
| Asia Pacific | $0 | $145,000 | $160,000 |
| Spain | — | — | $11,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Laboratory Services | $4,031,000 | $1,859,000 | — |
| Kitted Products | $24,000 | $0 | — |
| Laboratory Developed Test Services | $0 | $22,000 | — |
| Laboratory Developed Test Services | — | — | $36,000 |
| Pharma Services | — | — | $1,467,000 |
Key facts
CIK
1642380
CUSIP
68235C206
13F (30d)
27 filings
27 filers
Visit website
Investor relations